Viracta Therapeutics Form 3 SUNESIS PHARMACEUTICALS / Judith A. Fox ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fox Judith A.

(Last)

(First)

(Middle)

SUNESIS PHARMACEUTICALS, INC.

395 OYSTER POINT BOULEVARD, SUITE 400

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/14/2019

3. Issuer Name and Ticker or Trading Symbol
SUNESIS PHARMACEUTICALS INC [ SNSS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	40,268	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	11/30/2026	Common Stock	4,000	4	D
Stock Option (Right to Buy)	⁽²⁾	03/31/2027	Common Stock	30,000	4.1	D
Stock Option (Right to Buy)	⁽³⁾	07/10/2024	Common Stock	106	2.62	D
Stock Option (Right to Buy)	⁽⁴⁾	07/10/2024	Common Stock	12,682	2.62	D
Stock Option (Right to Buy)	⁽⁵⁾	07/31/2027	Common Stock	10,000	2.64	D
Stock Option (Right to Buy)	⁽⁶⁾	12/29/2027	Common Stock	195,000	3.69	D
Stock Option (Right to Buy)	⁽⁷⁾	12/31/2028	Common Stock	150,000	4	D

Explanation of Responses:

1. Fully vested.

2. One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2017. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

3. The shares vest monthly over three (3) years from July 10, 2017.

4. The shares vest monthly over two (2) years from July 10, 2017.

5. One fourth (1/4th) of the shares shall vest one (1) year from the vesting commencement date of July 31, 2017. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

6. One fourth (1/4th) of the shares shall vest one (1) year from the vesting commencement date of December 29, 2017. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

7. One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of December 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.

	/s/ Tina Gullotta (Attorney-in-Fact)	03/25/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Viracta Therapeutics (VIRX) Form 3SUNESIS PHARMACEUTICALS / Judith A. Fox ownership change